The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.
A key test of J&J’s targeted agent approaches, but Astra has a trick up its sleeve that could render this readout irrelevant.
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
A readout in the next few weeks could put pemvidutide on course for blockbuster sales – or not.
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
A pivotal readout approaches in COPD, where other biologicals have fallen short.
Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.